NZAX-listed TruScreen says 1st-qtr sales topped all of 2018's $800,000; shares jump

NZAX-listed TruScreen says 1st-qtr sales topped all of 2018's $800,000; shares jump
Jonathan Underhill
By Jonathan Underhill July 3 (BusinessDesk) - TruScreen, the NZAX-listed maker of a cervical cancer test, said sales in the three months ending June 30 have already exceeded the $800,000 it took in for the previous full year. Its shares jumped The Auckland-based company said it expects to have more than 600 of its devices deployed in China in the current 2019 year and by its estimation, it can get "a sustainable annuity income stream of approximately $1.4 million" for every 100 devices in hospitals.  China has been driving sales growth...